Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H7P6

UPID:
MB12B_HUMAN

ALTERNATIVE NAMES:
ESCRT-I complex subunit MVB12B; Protein FAM125B

ALTERNATIVE UPACC:
Q9H7P6; Q8N6S7

BACKGROUND:
The protein Multivesicular body subunit 12B, known alternatively as ESCRT-I complex subunit MVB12B or Protein FAM125B, is integral to the ESCRT-I complex. This complex is essential for the sorting of endocytic ubiquitinated cargos into multivesicular bodies, a process vital for cellular regulation and material recycling. MVB12B's role underscores its importance in the intricate web of cellular trafficking and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
The exploration of Multivesicular body subunit 12B's function offers a promising avenue for therapeutic innovation. Given its critical role in vesicular trafficking and cargo sorting, insights into MVB12B could lead to breakthroughs in treating diseases linked to cellular trafficking anomalies. The potential to harness MVB12B's mechanisms for therapeutic purposes is an exciting frontier in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.